v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Revenue $ 68,914 $ 242,732 $ 147,939 $ 487,025
Operating expenses:        
Cost of revenue 43,273 37,496 76,949 77,528
Selling, general and administrative 35,377 28,061 74,048 61,261
Research and development 4,194 4,274 8,339 7,969
Change in estimated fair value of contingent consideration (2,316) (7,800) (2,316) (7,800)
Total operating expenses 80,528 62,031 157,020 138,958
(Loss) income from operations (11,614) 180,701 (9,081) 348,067
Other income (expense):        
Interest expense (7,022) (4,434) (18,855) (7,098)
Interest income 6,791 0 12,836 0
Loss on extinguishment of debt 0 0 0 (208)
Change in payable to related parties pursuant to the Tax Receivable Agreement 101 0 (1,335) 2,340
Other expense (1,620) (1,275) (1,452) (1,268)
(Loss) income before income taxes (13,364) 174,992 (17,887) 341,833
Income tax (benefit) expense (1,421) 18,271 (4,596) 38,252
Net (loss) income (11,943) 156,721 (13,291) 303,581
Net (loss) income attributable to non-controlling interests (5,402) 85,481 (6,683) 165,479
Net (loss) income attributable to Maravai LifeSciences Holdings, Inc. $ (6,541) $ 71,240 $ (6,608) $ 138,102
Net (loss) income per Class A common share attributable to Maravai LifeSciences Holdings, Inc.:        
Basic (in usd per share) $ (0.05) $ 0.54 $ (0.05) $ 1.05
Diluted (in usd per share) $ (0.05) $ 0.53 $ (0.05) $ 1.03
Weighted average number of Class A common shares outstanding:        
Basic (in shares) 131,864 131,524 131,802 131,506
Diluted (in shares) 131,864 255,361 131,802 255,324

Source